Repligen Soars 5% as RBC Raises Price Target to $200 After Full-Year Guidance Hike
Repligen (RGEN) shares rose 5% after RBC Capital raised its price target to $200, citing strong Q3 results and raised full-year guidance. The company reported 11% revenue growth and expects 12%-13% organic growth in 2026. Competitors like Avantor, Thermo Fisher, and Danaher are growing more slowly.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest a stronger growth trajectory, prompting analysts to lift price targets and investors to bid up the stock.
Market read
Repligen's earnings beat and guidance lift are fresh, material news likely to drive short‑term upside and influence peer valuations.
What to watch
Repligen's recent BioLife acquisition adds integration risk that could temper upside.
Background
Repligen reported a record Q3 with 11% revenue growth, beat expectations, and announced a higher 2026 revenue range of $844‑$852 million.
Ticker impact
RBC raised its price target to $200 after Repligen beat estimates and lifted full-year revenue guidance, driving a 5% share jump.
upward pressure as investors price in stronger growth and higher target
Guidance lift and analyst target increase are fresh, material news for a mid‑cap biotech, and the stock already rallied 5% on the announcement.
Market effects
Bioprocessing peers may face relative underperformance as Repligen outpaces them.
U.S. biotech sector gains modest boost from the surprise guidance lift.
Limited to investors focused on specialty biotech and growth stocks.
Counterpoint
The guidance hike may be optimistic given competitive pressure; a pullback could follow if growth slows.
Key entities
- analystRBC Capital Markets
Raised price target to $200 and maintained Outperform rating.
- acquired companyBioLife
Acquisition closed in October, contributing to 2027 revenue outlook.

